Friedreich's ataxia:: Idebenone treatment in early stage patients


Por: Artuch-Iriberri R, Aracil A, Mas A, Colomé C, Rissech M, Monrós E and Pineda M

Publicada: 1 ago 2002
Resumen:
Background: Antioxidant therapy has been applied to Friedreich's ataxia patients. We assessed the effect idebenone treatment in patients with Friedreich's ataxia. Methods: Design: open-label trial. Nine Friedreich's ataxia patients (age range 11 - 19 years) were treated with idebenone (5 mg/kg/day). Patients were evaluated before the start of the therapy and throughout one year of treatment by International Cooperative Ataxia Rating Scales (ICARS) scores, neurophysiological investigations and echocardiographic measurements. Serum idebenone concentrations were measured by HPLC with electrochemical detection. The number of GAA repeats at the frataxin gene was analyzed by PCR. Results: Serum idebenone concentrations ranged between 0.04-0.37 mumol/L. Significantly positive correlation was observed between idebenone values and the percentage of difference between the ICARS scores before and 12 months after the start of the therapy (r = 0.883 -, p = 0.002). Significant reduction was observed comparing the ICARS scores in baseline conditions and after 3 months of treatment (p = 0.017). No differences were observed in echocardiographic measurements after the start of the therapy. Conclusions: Cerebellar improvement was notable in mild patients after the first 3 months of therapy. Idebenone treatment at early stages of the disease seems to reduce the progression of cerebellar manifestations. Further blind trials with a greater number of patients and higher doses are needed to fully assess the therapeutic potential of idebenone in Friedreich's ataxia.

Filiaciones:
Univ Barcelona, Hosp Sant Joan de Deu, Dept Biochem, Barcelona 08950, Spain.
Univ Barcelona, Hosp Sant Joan de Deu, Dept Neurol, E-08007 Barcelona, Spain.
Univ Barcelona, Hosp Sant Joan de Deu, Dept Pharm, E-08007 Barcelona, Spain.
Univ Barcelona, Hosp Sant Joan de Deu, Dept Cardiol, E-08007 Barcelona, Spain.
Univ Barcelona, Hosp Sant Joan de Deu, Dept Genet, E-08007 Barcelona, Spain.
Univ Barcelona, Hosp Sant Joan de Deu, Dept Biochem, Barcelona 08950, Spain
Univ Barcelona, Hosp Sant Joan de Deu, Dept Neurol, E-08007 Barcelona, Spain
Univ Barcelona, Hosp Sant Joan de Deu, Dept Pharm, E-08007 Barcelona, Spain
Univ Barcelona, Hosp Sant Joan de Deu, Dept Cardiol, E-08007 Barcelona, Spain
Univ Barcelona, Hosp Sant Joan de Deu, Dept Genet, E-08007 Barcelona, Spain
ISSN: 0174304X





NEUROPEDIATRICS
Editorial
GEORG THIEME VERLAG KG, Oswald-Hesse-Strasse 50, D-70469 STUTTGART, GERMANY, Alemania
Tipo de documento: Article
Volumen: 33 Número: 4
Páginas: 190-193
WOS Id: 000178439600005
ID de PubMed: 12368988

MÉTRICAS